Alibaba's Damo Academy open-sources RADAR, a model that reads CT scans to detect ~150 abdominal conditions, including cancers
open-source
| Source: Techmeme | Original article
Alibaba's Damo Academy has open‑sourced RADAR, a vision‑language AI that reads CT scans to detect roughly 150 abdominal conditions, and in tests on nearly 40,000 exams it outperformed most radiologists.
Alibaba’s Damo Academy has released RADAR, a new medical vision‑language model that can analyse CT scans of the abdomen and flag roughly 150 conditions, cancers among them. The company says the system was evaluated on almost 40,000 real‑world examinations and achieved performance that surpasses most practising radiologists.
The open‑source release marks a shift toward broader accessibility of advanced AI tools in diagnostic imaging. By coupling visual analysis with natural‑language capabilities, RADAR can not only detect pathologies but also generate descriptive reports, potentially easing workloads in overstretched radiology departments. If the model lives up to the claims, it could accelerate early detection of abdominal cancers and streamline triage in hospitals that lack specialist expertise.
Stakeholders will be watching how quickly the research community adopts the code and whether independent validation confirms the reported accuracy gains. Regulatory scrutiny is another factor; medical AI tools must meet stringent safety standards before clinical deployment, and the open‑source nature of RADAR may prompt both faster peer review and heightened oversight. Additionally, the model’s performance across diverse patient populations and imaging equipment will be a key test of its generalisability.
Future developments to monitor include any partnerships between Alibaba and healthcare providers, updates that expand RADAR’s scope beyond the abdomen, and responses from radiology societies regarding integration of such AI assistants into routine practice. The rollout could set a precedent for how large tech firms contribute to medical AI ecosystems while navigating the balance between innovation and patient safety.
Sources
Back to AIPULSEN